Key Takeaways
- • Graph AI closed a $3 million seed funding round led by Bessemer Venture Partners, positioning the company to capture share in the $8 billion global pharmacovigilance market.
- • The investment will fund product innovation, engineering team expansion, and international market adoption of Graph's AI-driven drug safety platform.
- • Graph's platform automates adverse drug event (ADE) detection, signal reporting, and regulatory compliance, replacing manual labor-intensive processes currently outsourced by pharmaceutical companies to service firms.
- • Enterprise customers have reported up to 70% efficiency gains, 90% faster regulatory reporting, and measurable cost savings, with a pipeline spanning over 7,000 drugs across the customer base.
- • The company, founded in 2024 by Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO), exemplifies the emerging wave of AI-native life sciences challengers disrupting traditionally outsourced pharmaceutical workflows.
Summary
Graph AI, a California-based patient safety and pharmacovigilance startup, announced a $3 million seed funding round led by Bessemer Venture Partners on October 15, 2025. The investment enables the company to accelerate product development, expand its engineering team, and pursue aggressive global market expansion targeting the $8 billion pharmacovigilance sector.
Pharmacovigilance—the continuous monitoring, detection, and reporting of adverse drug events (ADEs) mandated by global regulators—remains a labor-intensive process across the pharmaceutical industry. Currently, drug manufacturers outsource this function to specialized service firms that deploy large teams to manually scrape data from disparate sources and compile regulatory reports. Graph's platform automates this workflow by deploying AI and intelligent automation for ADE processing, signal detection, and regulatory reporting while maintaining human oversight for regulatory-mandated checkpoints. This hybrid approach shifts the operational model from manual, error-prone processes to highly efficient, AI-driven systems that enhance both accuracy and speed while ensuring regulatory compliance.
Early traction demonstrates significant market demand. Graph has already secured enterprise customers and built a pipeline encompassing over 7,000 drugs. According to reported metrics, customers have achieved up to 70% efficiency gains, 90% faster regulatory reporting timelines, and substantial cost reductions while maintaining end-to-end traceability and audit readiness. Nithin Kaimal, Partner and COO at Bessemer Venture Partners India, noted the firm's conviction in Graph's approach: "We're excited to partner with Graph AI as they redefine labour-intensive and inefficient pharmacovigilance workflows through AI-native solutions that prioritize both accuracy and scalability."
The founding team brings significant enterprise software and life sciences experience. CEO Raghav Parvataraju, CTO Vijay Ponukumati, CPO Mohan Konyala, and CFO Ashutosh Bordekar previously held senior roles at organizations including Infosys, Google, and ServiceNow. Graph's strategy exemplifies a broader industry trend: replacing labor arbitrage with intelligence arbitrage in traditionally outsourced pharmaceutical operations. The capital infusion positions the company to accelerate this market transition and establish early dominance in an underserved, highly regulated sector.
Pharmacovigilance—the continuous monitoring, detection, and reporting of adverse drug events (ADEs) mandated by global regulators—remains a labor-intensive process across the pharmaceutical industry. Currently, drug manufacturers outsource this function to specialized service firms that deploy large teams to manually scrape data from disparate sources and compile regulatory reports. Graph's platform automates this workflow by deploying AI and intelligent automation for ADE processing, signal detection, and regulatory reporting while maintaining human oversight for regulatory-mandated checkpoints. This hybrid approach shifts the operational model from manual, error-prone processes to highly efficient, AI-driven systems that enhance both accuracy and speed while ensuring regulatory compliance.
Early traction demonstrates significant market demand. Graph has already secured enterprise customers and built a pipeline encompassing over 7,000 drugs. According to reported metrics, customers have achieved up to 70% efficiency gains, 90% faster regulatory reporting timelines, and substantial cost reductions while maintaining end-to-end traceability and audit readiness. Nithin Kaimal, Partner and COO at Bessemer Venture Partners India, noted the firm's conviction in Graph's approach: "We're excited to partner with Graph AI as they redefine labour-intensive and inefficient pharmacovigilance workflows through AI-native solutions that prioritize both accuracy and scalability."
The founding team brings significant enterprise software and life sciences experience. CEO Raghav Parvataraju, CTO Vijay Ponukumati, CPO Mohan Konyala, and CFO Ashutosh Bordekar previously held senior roles at organizations including Infosys, Google, and ServiceNow. Graph's strategy exemplifies a broader industry trend: replacing labor arbitrage with intelligence arbitrage in traditionally outsourced pharmaceutical operations. The capital infusion positions the company to accelerate this market transition and establish early dominance in an underserved, highly regulated sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.